Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

697 ARTÍCULOS , VIENDO DEL 526 AL 540

Clinical Significance of the Plasma Biomarker Panels in Amyloid-Negative and Tau PET-Positive Amnestic Patients: Comparisons with Alzheimer's Disease and Unimpaired Cognitive Controls

Chang HI, Huang KL, Huang CG, Huang CW, Huang SH, Lin KJ, Chang CC.

Int J Mol Sci. 2024 May 21;25(11):5607. doi: 10.3390/ijms25115607.

From Gut Microbiota to Brain Waves: The Potential of the Microbiome and EEG as Biomarkers for Cognitive Impairment

Krothapalli M, Buddendorff L, Yadav H, Schilaty ND, Jain S.

Int J Mol Sci. 2024 Jun 18;25(12):6678. doi: 10.3390/ijms25126678.

An Integrative Review about Electrophysiological Biomarkers of Cognitive Impairment in Alzheimer's Disease: A Developing Relationship

Holston EC.

Issues Ment Health Nurs. 2024 Jul;45(7):746-757. doi: 10.1080/01612840.2024.2352011. Epub 2024 Jul 2.

A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer's Disease

Galasko D, Farlow MR, Lucey BP, Honig LS, Elbert D, Bateman R, Momper J, Thomas RG, Rissman RA, Pa J, Aslanyan V, Balasubramanian A, West T, Maccecchini M, Feldman HH.

Alzheimers Res Ther. 2024 Jul 5;16(1):151. doi: 10.1186/s13195-024-01490-z.

Blood Astrocyte Biomarkers in Alzheimer Disease: A Systematic Review and Meta-Analysis

Holper S, Loveland P, Churilov L, Italiano D, Watson R, Yassi N.

Neurology. 2024 Aug 13;103(3):e209537. doi: 10.1212/WNL.0000000000209537. Epub 2024 Jul 10.

Non-Genetic Risk Factors of Alzheimer's Disease: An Updated Umbrella Review

He SY, Su WM, Wen XJ, Lu SJ, Cao B, Yan B, Chen YP.

J Prev Alzheimers Dis. 2024;11(4):917-927. doi: 10.14283/jpad.2024.100.

Predicting Brain Amyloid Status Using the National Institute of Health Toolbox (NIHTB) for Assessment of Neurological and Behavioral Function

Cheng Y, Ho E, Weintraub S, Rentz D, Gershon R, Das S, Dodge HH.

J Prev Alzheimers Dis. 2024;11(4):943-957. doi: 10.14283/jpad.2024.77.

A phase 2, open-label study of anti-inflammatory NE3107 in patients with dementias

Haroon J, Jordan K, Mahdavi K, Rindner E, Becerra S, Surya JR, Zielinski M, Venkatraman V, Goodenowe D, Hofmeister K, Zhang J, Ahlem C, Reading C, Palumbo J, Pourat B, Kuhn T, Jordan S.

Medicine (Baltimore). 2024 Jul 26;103(30):e39027. doi: 10.1097/MD.0000000000039027.

Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care

Palmqvist S, Tideman P, Mattsson-Carlgren N, Schindler SE, Smith R, Ossenkoppele R, Calling S, West T, Monane M, Verghese PB, Braunstein JB, Blennow K, Janelidze S, Stomrud E, Salvadó G, Hansson O.

JAMA. 2024 Oct 15;332(15):1245-1257. doi: 10.1001/jama.2024.13855.

Human Leukocyte Antigen and microRNAs as Key Orchestrators of Mild Cognitive Impairment and Alzheimer's Disease: A Systematic Review

Cătană CS, Marta MM, Văleanu M, Dican L, Crișan CA.

Int J Mol Sci. 2024 Aug 5;25(15):8544. doi: 10.3390/ijms25158544.

MicroRNA-455-3P as a peripheral biomarker and therapeutic target for mild cognitive impairment and Alzheimer's disease

Islam MA, Sultana OF, Bandari M, Kshirsagar S, Manna PR, Reddy PH.

Ageing Res Rev. 2024 Sep;100:102459. doi: 10.1016/j.arr.2024.102459. Epub 2024 Aug 15.

Cerebrospinal fluid in the differential diagnosis of Alzheimer's disease: an update of the literature

Milos T, Vuic B, Balic N, Farkas V, Nedic Erjavec G, Svob Strac D, Nikolac Perkovic M, Pivac N.

Expert Rev Neurother. 2024 Nov;24(11):1063-1079. doi: 10.1080/14737175.2024.2400683. Epub 2024 Sep 4.

Lewy body pathology exacerbates brain hypometabolism and cognitive decline in Alzheimer's disease

Collij LE, Mastenbroek SE, Mattsson-Carlgren N, Strandberg O, Smith R, Janelidze S, Palmqvist S, Ossenkoppele R, Hansson O.

Nat Commun. 2024 Sep 14;15(1):8061. doi: 10.1038/s41467-024-52299-1.

Japanese Subgroup Analyses from EMERGE and ENGAGE, Phase 3 Clinical Trials of Aducanumab in Patients with Early Alzheimer's Disease

Toda Y, Iwatsubo T, Nakamura Y, Matsuda N, Miyata M, Jin M, Chen T, Kuribayashi K, Tian Y, Hughes R, Yamamoto J, Muralidharan KK, Rubel C, Hutchison RM, Budd Haeberlein S.

J Prev Alzheimers Dis. 2024;11(5):1260-1269. doi: 10.14283/jpad.2024.106.

Clinical and research application of fluid biomarkers in autosomal dominant Alzheimer's disease and Down syndrome

Carmona-Iragui M, O'Connor A, Llibre-Guerra J, Lao P, Ashton NJ, Fortea J, Sánchez-Valle R.

EBioMedicine. 2024 Oct;108:105327. doi: 10.1016/j.ebiom.2024.105327. Epub 2024 Oct 3.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias